scholarly journals Prediabetes: lifestyle, pharmacotherapy or regulation?

2019 ◽  
Vol 10 ◽  
pp. 204201881986302 ◽  
Author(s):  
Jonathan E. Shaw

The rapidly rising number of people with diabetes worldwide has led to multiple attempts to identify effective means of preventing type 2 diabetes. Lifestyle interventions have shown impressive efficacy in multiple clinical trials of people with impaired glucose tolerance, but, as currently formulated, appear to have very little impact on impaired fasting glucose. Attempts to roll out lifestyle interventions beyond clinical trials have generally recruited too few people to have a chance of influencing the population prevalence of diabetes. Several drugs have also been shown to reduce the incidence of diabetes, but until such drugs can be shown to prevent the clinical consequences of diabetes, it is unlikely that guidelines will recommend their widespread use for diabetes prevention. Population-level interventions, including education and regulation, are attractive, as they have the potential to influence a high proportion of the population. Favourable effects of a sugar sweetened beverage tax on consumption are encouraging, but data on its influence on diabetes are not yet available.

Open Medicine ◽  
2008 ◽  
Vol 3 (1) ◽  
pp. 9-19 ◽  
Author(s):  
Siamak Bidel ◽  
Gang Hu ◽  
Jaakko Tuomilehto

AbstractCoffee is a complex mixture of potentially active chemicals. It contains significant amounts of phenolic polymers, chlorogenic acid and also caffeine. Agricultural factors, roasting, blending, and brewing determine coffee’s chemical composition. Recent epidemiological studies suggest that habitual coffee consumption may help to prevent some chronic diseases including type 2 diabetes. Despite reports from the clinical trials of the effect of caffeine on decreasing insulin sensitivity, long-term prospective studies revealed that coffee may improve fasting glucose, glucose tolerance and insulin sensitivity as well. In the most recent publication habitual coffee drinkers have a lower total and cardiovascular mortality rate among diabetic subjects.


2021 ◽  
Vol 50 (Supplement_1) ◽  
Author(s):  
Mingling Chen ◽  
Gebresilasea Ukke ◽  
Surbhi Sood ◽  
Christie Bennett ◽  
Mahnaz Khomami ◽  
...  

Abstract Background The risk of type 2 diabetes varies by ethnicity, but ethnic differences in response to lifestyle interventions for diabetes prevention remain unclear. This systematic review and meta-analysis aimed to assess differences in the effects of lifestyle interventions on diabetes incidence, glycemic outcomes and anthropometric measures between ethnic groups. Methods MEDLINE, EMBASE, Pubmed, CINAHL, PsycInfo and EBM Reviews were searched (to June 2020) with no language restriction for randomized and non-randomized controlled trials on lifestyle interventions involving diet and/or physical activity in adults at risk of type 2 diabetes. Ethnicity was categorized into European, South Asian, Other Asian, Middle Eastern, Latin American and African groups based on the World Bank regions. Risk ratios for diabetes incidence and mean differences for glycemic outcomes (fasting glucose, 2-h glucose, HbA1c) and anthropometric measures (weight, BMI, waist circumference) were pooled using random-effects meta-analysis. Results Sixty articles representing 43 studies (18,691 participants) were included in meta-analyses. Overall, lifestyle interventions resulted in significant improvement in diabetes incidence, glycemic outcomes and anthropometric measures compared with controls (all P<0.01). Significant subgroup differences by ethnicity were found for 2-h glucose, weight, BMI and waist circumference (all P<0.05) but not for diabetes incidence, fasting glucose and HbA1c (all P>0.05). Conclusions Lifestyle interventions are similarly effective in reducing diabetes incidence, fasting glucose and HbA1c for all ethnic groups, however, 2-h glucose and anthropometric outcomes should be optimized in certain ethnic groups. Key messages Lifestyle intervention is likely effective in preventing the progression to type 2 diabetes equally across all ethnic groups.


Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1535-P ◽  
Author(s):  
HYE-IN JUNG ◽  
JAEHYUN BAE ◽  
EUGENE HAN ◽  
GYURI KIM ◽  
JI-YEON LEE ◽  
...  

Diabetes ◽  
2020 ◽  
Vol 69 (Supplement 1) ◽  
pp. 1476-P
Author(s):  
AOIFE M. EGAN ◽  
CHRISTINA WOOD-WENTZ ◽  
KENT R. BAILEY ◽  
ADRIAN VELLA

2019 ◽  
Author(s):  
Ya-Sian Chang ◽  
Li-Yun Hsiao ◽  
Chien-Yu Lin ◽  
Mu-Chin Shih ◽  
Ming-Chia Hsieh ◽  
...  

2020 ◽  
Vol 27 ◽  
Author(s):  
Peyman Nowrouzi-Sohrabi ◽  
Reza Tabrizi ◽  
Mohammad Jalali ◽  
Navid Jamali ◽  
Shahla Rezaei ◽  
...  

Introduction: A systematic review and meta-analysis of clinical trials was undertaken to evaluate the effect of diacerein intake on cardiometabolic profiles in patients with type 2 diabetes mellitus (T2DM). Methods: Electronic databases such as PubMed, EMBASE, Scopus, Web of Science, Google Scholar, and Cochrane Central Register of Controlled Trials were searched from inception to 31 July 2019. Statistical heterogeneity was evaluated using Cochran’s Q test and I-square (I2 ) statistic. Data were pooled using random-effect models and weighted mean difference (WMD). Results: From 1,733 citations, seven clinical trials were eligible for inclusion and meta-analysis. A significant reduction in hemoglobin A1c (HbA1c) (WMD -0.73; 95%CI -1.25 to -0.21; P= 0.006; I2 = 72.2%) and body mass index (BMI) (WMD -0.55; 95%CI -1.03 to -0.07; P= 0.026; I2 = 9.5%) were identified. However, no significant effect of diacerein intake was identified on fasting blood sugar (FBS) (WMD - 9.00; 95%CI -22.57 to 4.57; P= 0.194; I2 = 60.5%), homeostatic model assessment for insulin resistance (HOMA-IR) (WMD 0.39; 95%CI 0.95 to 1.73; P= 0.569; I2 = 2.2%), body weight (WMD -0.54; 95%CI -1.10 to 0.02; P= 0.059), triglycerides (WMD -0.56; 95%CI -24.16 to 23.03; P= 0.963; I2 = 0.0%), total-cholesterol (WMD -0.21; 95%CI -12.19 to 11.78; P= 0.973; I2 = 0.0%), HDL-cholesterol (WMD -0.96; 95%CI -2.85 to 0.93; P= 0.321; I2 = 0.0%), and LDL-cholesterol levels (WMD -0.09; 95%CI -8.43 to 8.25; P= 0.983; I2 = 37.8%). Conclusion: Diacerein intake may reduce HbA1c and BMI; however, no evidence of effect was observed for FBS, HOMA-IR, body weight, triglycerides, total-cholesterol, HDL-cholesterol or LDL-cholesterol.


Sign in / Sign up

Export Citation Format

Share Document